Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma
Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are considered a first-line treatment in the management of glaucoma and have the best efficacy in reducing intraocular pressure....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1015338/full |
| _version_ | 1798020724871397376 |
|---|---|
| author | Lin Zhou Wenyi Zhan Xin Wei |
| author_facet | Lin Zhou Wenyi Zhan Xin Wei |
| author_sort | Lin Zhou |
| collection | DOAJ |
| description | Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are considered a first-line treatment in the management of glaucoma and have the best efficacy in reducing intraocular pressure. When comparing these therapeutic agents between them, long-term therapy with 0.03% bimatoprost is the most effective followed by treatment with 0.005% latanoprost and 0.004% travoprost. The prevalence of adverse events is lower for latanoprost than for other prostaglandin analogs. However, some patients do not respond to the treatment with prostaglandin analogs (non-responders). Intraocular pressure-lowering efficacy differs significantly between individuals partly owing to genetic factors. Rs1045642 in ABCB1, rs4241366 in SLCO2A1, rs9503012 in GMDS, rs10306114 in PTGS1, rs11568658 in MRP4, rs10786455 and rs6686438 in PTGFR were reported to be positive with the response to prostaglandin analogs in patients with glaucoma. A negative association was found between single nucleotide polymorphisms of PTGFR (rs11578155 and rs6672484) and the response to prostaglandin analogs in patients with glaucoma. The current review is an analysis of the information relevant to prostaglandin analog treatments based on previous literatures. It describes in detail the clinical pharmacology and pharmacogenetics of drugs belonging to this therapeutical class to provide a sound pharmacological basis for their proper use in ophthalmological clinical practice. |
| first_indexed | 2024-04-11T17:02:16Z |
| format | Article |
| id | doaj.art-2f8ade26e58e4849a9b0a242d673b22c |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T17:02:16Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-2f8ade26e58e4849a9b0a242d673b22c2022-12-22T04:13:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.10153381015338Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucomaLin Zhou0Wenyi Zhan1Xin Wei2Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Medicine, Sichuan University, Chengdu, ChinaDepartment of Ophthalmology, West China Hospital, Sichuan University, Chengdu, ChinaGlaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are considered a first-line treatment in the management of glaucoma and have the best efficacy in reducing intraocular pressure. When comparing these therapeutic agents between them, long-term therapy with 0.03% bimatoprost is the most effective followed by treatment with 0.005% latanoprost and 0.004% travoprost. The prevalence of adverse events is lower for latanoprost than for other prostaglandin analogs. However, some patients do not respond to the treatment with prostaglandin analogs (non-responders). Intraocular pressure-lowering efficacy differs significantly between individuals partly owing to genetic factors. Rs1045642 in ABCB1, rs4241366 in SLCO2A1, rs9503012 in GMDS, rs10306114 in PTGS1, rs11568658 in MRP4, rs10786455 and rs6686438 in PTGFR were reported to be positive with the response to prostaglandin analogs in patients with glaucoma. A negative association was found between single nucleotide polymorphisms of PTGFR (rs11578155 and rs6672484) and the response to prostaglandin analogs in patients with glaucoma. The current review is an analysis of the information relevant to prostaglandin analog treatments based on previous literatures. It describes in detail the clinical pharmacology and pharmacogenetics of drugs belonging to this therapeutical class to provide a sound pharmacological basis for their proper use in ophthalmological clinical practice.https://www.frontiersin.org/articles/10.3389/fphar.2022.1015338/fullglaucomaprostaglandin analoguesefficiencysafetypharmacogeneticsvisual loss |
| spellingShingle | Lin Zhou Wenyi Zhan Xin Wei Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma Frontiers in Pharmacology glaucoma prostaglandin analogues efficiency safety pharmacogenetics visual loss |
| title | Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma |
| title_full | Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma |
| title_fullStr | Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma |
| title_full_unstemmed | Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma |
| title_short | Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma |
| title_sort | clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma |
| topic | glaucoma prostaglandin analogues efficiency safety pharmacogenetics visual loss |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1015338/full |
| work_keys_str_mv | AT linzhou clinicalpharmacologyandpharmacogeneticsofprostaglandinanaloguesinglaucoma AT wenyizhan clinicalpharmacologyandpharmacogeneticsofprostaglandinanaloguesinglaucoma AT xinwei clinicalpharmacologyandpharmacogeneticsofprostaglandinanaloguesinglaucoma |